The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future (Q37796015)

23 August 2017

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future (English)

1 reference

23 August 2017

1 reference

1 reference

1

Susan H Fox

1 reference

23 August 2017

2

Jonathan M Brotchie

1 reference

23 August 2017

1 January 2010

1 reference

Progress in Brain Research

23 August 2017

1 reference

23 August 2017

184

1 reference

23 August 2017

133-157

1 reference

Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Induction of chorea and dystonia in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Nondopaminergic mechanisms in levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Use of 11C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Primate globus pallidus and subthalamic nucleus: functional organization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Trihexyphenidyl potentiation of L-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effects of (±)-Idazoxan Alone and in Combination with L-DOPA Methyl Ester in MPTP-Induced Hemiparkinsonian Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Nonhuman primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Basal ganglia lesions after MPTP administration in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Marmoset monkey models of Parkinson's disease: which model, when and why?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Tremor induced by tremorine and its antagonism by anti-Parkinson drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Serotonergic sprouting in primate MTP-induced hemiparkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Dopamine transporter mutants selectively enhance MPP+ transport

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Beta2* and beta4* nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Overview of the extranigral aspects of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

An objective measurement of locomotion behavior for hemiparkinsonian cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Objective quantification of arm rigidity in MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The pedunculopontine nucleus in Parkinson's disease: primate studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Evolution of the response to levodopa during the first 4 years of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Parkinsonian akinesia, rigidity and tremor in the monkey. Histopathological and neuropharmacological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism: II. Effects of reward preference

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Experimental and histological study of midbrain dyskinesias.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Classification of fluctuations in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

Distinct monoamine oxidase A and B populations in primate brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984007-5

7 January 2021

10.1016/S0079-6123(10)84007-5

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20887873